Research programme: skin disease therapeutics - Evotec AG/MaRS Innovation

Drug Profile

Research programme: skin disease therapeutics - Evotec AG/MaRS Innovation

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Evotec AG
  • Developer Evotec AG; MaRS Innovation
  • Class Skin disorder therapies
  • Mechanism of Action Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Atopic dermatitis; Congenital ichthyosiform erythroderma

Most Recent Events

  • 15 Feb 2018 Early research in Atopic dermatitis in Germany (Topical)
  • 15 Feb 2018 Early research in Congenital ichthyosiform erythroderma in Germany (Topical)
  • 30 Sep 2017 Evotec AG and MaRS Innovation enter into a collaboration agreement for the development of kallikrein inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top